Dr. Reddy’s in Patent Suit over Vimovo
Plaintiffs: AstraZeneca AB, AstraZeneca LP, KBI-E andPozen
Defendants: Dr. Reddy’s Laboratories Inc. and Dr. Reddy’s Laboratories Ltd
Case Number: 3:13-cv-00091
Date Filed: January 04, 2013
Court: New Jersey District Court
Patents-in-Suit: US5714504, US6369085, US7411070, US6926907 and US7745466
Patent Number
Current Assignee[*] |
Issued
Date |
Expiration
Date[†] |
Case
Type |
Title
|
Feb 03, 1998 |
Feb 03, 2015 |
Infringement |
Compositions |
|
Apr 09, 2002 |
May 30, 2017 |
Infringement |
Form of S-omeprazole |
|
|
AstraZeneca AB (as per face page)
|
Aug 12, 2008 |
May 30, 2017 |
Infringement |
Form of S-omeprazole |
Aug 09, 2005 |
May 31, 2022 |
Infringement |
Pharmaceutical compositions for the
coordinated delivery of NSAIDs |
|
|
AstraZeneca AB (as per face page)
|
Jun 29, 2010 |
May 30, 2017 |
Declaratory Judgment |
Form of S-omeprazole
|
Table information sourced from Maxval’s Assignment Database.
KBI-E is exclusive licensee of the ’466, ‘070, ‘085 and ‘504 patents.
About the Parties:
AstraZeneca AB manufactures and distributes pharmaceutical products. It also undertakes research and development
activities. The company was founded in 1913 and formerly known as Astra AB. AstraZeneca AB operates as a subsidiary of AstraZeneca plc.
activities. The company was founded in 1913 and formerly known as Astra AB. AstraZeneca AB operates as a subsidiary of AstraZeneca plc.
AstraZeneca LP is a pharmaceutical company engaged in discovering, developing, producing, and marketing medications. It offers gastrointestinal, cardiovascular/metabolic, neuroscience, mental illness, respiratory, oncology, and infectious disease medicines. The company was founded in 1912 and operates as a subsidiary of AstraZeneca plc.
Pozen is a pharmaceutical company that develops products for the treatment of acute and chronic pain and other pain-related conditions in the United States. Its products include Treximet and VIMOVO. It has collaborations with AstraZeneca AB for the development and commercialization of proprietary fixed dose combinations of the proton pump inhibitor esomeprazole magnesium with the NSAID naproxen.
Dr. Reddy’s Laboratories (DRL) is an integrated pharmaceutical company focused on providing medicines through its three business segments: Global Generics segment, Pharmaceutical Services and Active Ingredients (PSAI) segment
and Proprietary Products segment. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas.
As in Complaint:
AstraZeneca LP is the current holder[‡] of New Drug Application (NDA) no. 022511 for Vimovo® delayed release tablets (source: Maxval’s Patent Marker) that is approved by FDA. Vimovo (see Fig. 1) contains a combination of esomeprazole and naproxen. It works by reducing substances in the body that cause inflammation, pain, and fever and decreases the amount of acid produced in the stomach. Plaintiffs allege that DRL seeks FDA approval to market a generic version of Vimovo® delayed release tablets with the Abbreviated New Drug Application (ANDA) no. 204206 that infringes the above patents.
Other Cases Filed:
Plaintiffs and Defendants have together or individually filled cases against each other. Cases highlighted in complaint are follows:
Plaintiff
|
Defendant
|
Case
Number |
Date
Filed |
Status
|
AstraZeneca AB
|
Dr. Reddy’s Labs Inc.
|
Apr 21, 2011
|
Pending
|
|
AstraZeneca AB
|
Dr. Reddy’s Labs, Ltd and Dr. Reddy’s Labs, Inc.
|
Jan 17, 2008
|
Closed
|
|
AstraZeneca UK and AstraZeneca LP
|
Dr. Reddy’s Labs, Ltd and Dr. Reddy’s Labs, Inc.
|
Jun 27, 2008
|
Pending
|
|
Dr. Reddy’s Labs Ltd and Dr. Reddy’s Labs Inc.
|
AstraZeneca AB
|
May 19, 2008
|
Closed
|
If you are interested in knowing more about the cases filed, please contact us.
To get alerts on cases filed, subscribe to our Litigation Alerts.
[*] MaxVal offers Patent Assignment Alert service where subscribers receive email alerts when assignments relating to target applications, patents or entities of interest are recorded.
[†] Expected expiration date. Patent Term Estimator is a free web-based tool that automatically calculates patent terms and expiration dates for U.S. utility patents.
[*] MaxVal offers Patent Assignment Alert service where subscribers receive email alerts when assignments relating to target applications, patents or entities of interest are recorded.
[†] Expected expiration date. Patent Term Estimator is a free web-based tool that automatically calculates patent terms and expiration dates for U.S. utility patents.
[‡] Patent Marker provides an online environment for patentees to virtually mark products and search for patent related information.
Comment
-
Comment by Amanpreet Singh on January 22, 2013 at 10:09am -
vimoco belongs to the astra zenecea .And they got the patent for this if Dr.reddy's wants to get patent on same druge this will against the law and Astra may sue them
Support
Add your Twitter profile!
Events
© 2013 Created by Mikk Putk.
You need to be a member of Intellectual Property Insiders to add comments!
Join Intellectual Property Insiders